Physician profile
Sheetal R Joshi
NPI 1174750442
$1,204.79
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $51.45 · 2021: $91.93 · 2022: $175.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $262.34 | 2019-2022 | |
| Alkermes, INC. | $186.86 | 2019-2022 | |
| Allergan, INC. | $163.04 | 2019-2020 | |
| Lundbeck LLC | $142.39 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $124.80 | 2019 | |
| Neurocrine Biosciences, INC. | $69.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $66.72 | 2019-2022 | |
| Abbvie INC. | $60.47 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.73 | 2019-2022 | |
| Shire North American Group INC | $26.15 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.10 | 2022 | |
| Vanda Pharmaceuticals INC. | $11.72 | 2019 | |
| Neuronetics, INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.